CN101534837B - 用于治疗结节性痤疮的阿奇霉素 - Google Patents

用于治疗结节性痤疮的阿奇霉素 Download PDF

Info

Publication number
CN101534837B
CN101534837B CN2007800406070A CN200780040607A CN101534837B CN 101534837 B CN101534837 B CN 101534837B CN 2007800406070 A CN2007800406070 A CN 2007800406070A CN 200780040607 A CN200780040607 A CN 200780040607A CN 101534837 B CN101534837 B CN 101534837B
Authority
CN
China
Prior art keywords
acne
azithromycin
purposes
nodules
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800406070A
Other languages
English (en)
Chinese (zh)
Other versions
CN101534837A (zh
Inventor
D·W·奥斯本
G·J·道
B·乔杜里
B·卡尔瓦雷塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Pharmaceutical Sciences Inc
Original Assignee
Dow Pharmaceutical Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Pharmaceutical Sciences Inc filed Critical Dow Pharmaceutical Sciences Inc
Publication of CN101534837A publication Critical patent/CN101534837A/zh
Application granted granted Critical
Publication of CN101534837B publication Critical patent/CN101534837B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
CN2007800406070A 2006-10-03 2007-09-24 用于治疗结节性痤疮的阿奇霉素 Expired - Fee Related CN101534837B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US84906506P 2006-10-03 2006-10-03
US60/849,065 2006-10-03
US11/635,127 US7704959B2 (en) 2006-10-03 2006-12-06 Azithromycin for the treatment of nodular acne
US11/635,127 2006-12-06
PCT/US2007/020583 WO2008042139A2 (en) 2006-10-03 2007-09-24 Azithromycin for the treatment of nodular acne

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100346744A Division CN102614210A (zh) 2006-10-03 2007-09-24 用于治疗结节性痤疮的阿奇霉素

Publications (2)

Publication Number Publication Date
CN101534837A CN101534837A (zh) 2009-09-16
CN101534837B true CN101534837B (zh) 2012-04-04

Family

ID=39261797

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2012100346744A Pending CN102614210A (zh) 2006-10-03 2007-09-24 用于治疗结节性痤疮的阿奇霉素
CN2007800406070A Expired - Fee Related CN101534837B (zh) 2006-10-03 2007-09-24 用于治疗结节性痤疮的阿奇霉素

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2012100346744A Pending CN102614210A (zh) 2006-10-03 2007-09-24 用于治疗结节性痤疮的阿奇霉素

Country Status (18)

Country Link
US (2) US7704959B2 (enExample)
EP (2) EP2086552B1 (enExample)
JP (1) JP2010505827A (enExample)
KR (1) KR20090064592A (enExample)
CN (2) CN102614210A (enExample)
AT (1) ATE533496T1 (enExample)
AU (1) AU2007302663B2 (enExample)
BR (1) BRPI0719535A2 (enExample)
CA (1) CA2664673A1 (enExample)
CY (1) CY1112650T1 (enExample)
DK (1) DK2086552T3 (enExample)
ES (2) ES2377470T3 (enExample)
MX (1) MX2009003484A (enExample)
PL (2) PL2420240T3 (enExample)
PT (1) PT2086552E (enExample)
RU (1) RU2009116629A (enExample)
SI (1) SI2086552T1 (enExample)
WO (1) WO2008042139A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
US8143227B2 (en) * 2007-09-05 2012-03-27 Dow Pharmaceutical Sciences, Inc. Azithromycin for treatment of skin disorders
CN107281155B (zh) * 2017-06-06 2020-04-10 扬子江药业集团四川海蓉药业有限公司 一种阿奇霉素片及其制备方法
JP2020527607A (ja) * 2017-07-21 2020-09-10 アルミラール・リミテッド・ライアビリティ・カンパニーＡｌｍｉｒａｌｌ， Ｌｌｃ 非炎症性病変の処置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474758A (en) 1981-11-19 1984-10-02 American Cyanamid Company Haemophilus influenzae type b and pertussis outer membrane component combined vaccine
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4474766A (en) 1983-06-27 1984-10-02 Merck & Co., Inc. Anti-inflammatory/analgesic combination of cyclo-(N-methyl-Ala-Tyr-D-Trp-Lys-Val-Phe) and a selected non-steroidal anti-inflammatory drug (NSAID)
MX12213A (es) 1987-07-09 1993-05-01 Pfizer Metodo de preparacion de dihidrato de azitromicina cristalino
FR2710841B1 (fr) * 1993-10-05 1995-11-17 Oreal Composition cosmétique ou pharmaceutique pour la peau, anhydre et stable, à base de rétinol et son utilisation en vue du traitement des maladies de la peau.
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
NZ528197A (en) * 2001-04-05 2007-04-27 Collagenex Pharm Inc Use of a tetracycline compound of treating acne
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
US9035741B2 (en) * 2003-06-27 2015-05-19 Stryker Corporation Foot-operated control console for wirelessly controlling medical devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INNOCENZI等.moderate acne vulgaris：efficacy，safety and compliance of a systemic treatment with azithromycin for 12 weeks.《Dermatologia Clinica》.2005,第25卷(第3期),126-130. *
RAFIEI等.Azithromycin versus tetracycline in treatment of acne vulgaris.《Journal of Dematologiacal Treatment》.2006,第17卷(第4期),217-221. *

Also Published As

Publication number Publication date
EP2086552A2 (en) 2009-08-12
CY1112650T1 (el) 2016-02-10
EP2420240A1 (en) 2012-02-22
EP2086552A4 (en) 2009-11-04
RU2009116629A (ru) 2010-11-10
WO2008042139A2 (en) 2008-04-10
HK1130667A1 (en) 2010-01-08
US7704959B2 (en) 2010-04-27
BRPI0719535A2 (pt) 2014-01-14
EP2420240B1 (en) 2016-05-11
AU2007302663A1 (en) 2008-04-10
DK2086552T3 (da) 2012-01-09
PL2420240T3 (pl) 2016-10-31
ES2377470T3 (es) 2012-03-27
US20080081790A1 (en) 2008-04-03
KR20090064592A (ko) 2009-06-19
MX2009003484A (es) 2009-10-26
SI2086552T1 (sl) 2012-01-31
PL2086552T3 (pl) 2012-03-30
US20100216732A1 (en) 2010-08-26
WO2008042139A3 (en) 2008-10-16
AU2007302663B2 (en) 2012-07-12
CN102614210A (zh) 2012-08-01
JP2010505827A (ja) 2010-02-25
ES2574677T3 (es) 2016-06-21
PT2086552E (pt) 2011-12-19
CA2664673A1 (en) 2008-04-10
EP2086552B1 (en) 2011-11-16
ATE533496T1 (de) 2011-12-15
CN101534837A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
Thielitz et al. Topical retinoids in acne–an evidence‐based overview
Cunliffe et al. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1%, versus lymecycline plus gel vehicle
Benner et al. Overview of the treatment of acne vulgaris
EP2240018B1 (en) Composition comprising an analgesic and an antihistamine
US9132139B2 (en) Maintenance therapy regime/regimen for the treatment of acne
CN101534837B (zh) 用于治疗结节性痤疮的阿奇霉素
MX2007004586A (es) Metodo que usa adapaleno en terapia de mantenimiento del acne.
CN101835475A (zh) 用于治疗皮肤病的阿奇霉素
McKeage et al. Doxycycline 40 mg Capsules (30 mg Immediate-Release/10 mg Delayed-Release Beads) Anti-Inflammatory Dose in Rosacea
RU2481832C2 (ru) Применение адапалена и пероксида бензоила для продолжительного лечения угрей обыкновенных
Tolino et al. An open-label study comparing oral zinc to lymecycline in the treatment of acne vulgaris
JP2009514963A (ja) 肉芽腫性酒さの治療ためのアジスロマイシン
HK1162921A (en) Azithromycin for the treatment of nodular acne
HK1130667B (en) Azithromycin for the treatment of nodular acne
JP6951332B2 (ja) 局所用ダプソン組成物を使用して尋常性座瘡を処置する方法
Saadawi et al. An Overview about Possible Roles of Dapsone and Adapalene in Treatment of Acne Vulgaris: A Review Article
Rockerbie A Family Physician's Approach to the Treatment of Acne
do Nascimento et al. Acne recurrence after treatment with oral isotretinoin: 5-year follow-up
Statsenko et al. Isotretinoin is the gold standard for acne therapy. Treating severe acne
HK1148645B (en) Composition comprising an analgesic and an antihistamine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120404

Termination date: 20120924